Monograph Details
|
|
Musculoskeletal Disorders
> Muscle spasms
|
|
ZANAFLEX CAPSULES |
| Manufacturer |
|
Acorda Therapeutics |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
α2-adrenergic agonist. |
| Generic Name |
|
Tizanidine HCl 2mg, 4mg, 6mg; caps. |
| Also |
|
• ZANAFLEX TABLETS
|
| Indications |
|
Muscle spasticity (due to its short duration of action reserve for when relief is most important). |
| Children |
|
Not recommended. |
| Adults |
|
Initially: usually 4mg, may increase by 2–4mg as needed every 6–8 hrs to a max of 3 doses in 24hrs; max 12mg/dose and 36mg/day. Renal impairment (CrCl <25mL/min): reduce dose. May sprinkle contents of capsules on applesauce (may affect absorption). Tabs and caps not bioequivalent under fed conditions. See literature. |
| Contraindications |
|
Concomitant fluvoxamine, ciprofloxacin. |
| Precautions |
|
Hepatic dysfunction. Monitor ophthalmic and liver function (aminotransferases at baseline, 1, 3, 6 months, then periodically) and for orthostatic hypotension. Renal dysfunction. Cardiovascular disease. Avoid abrupt cessation. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Avoid other α2-agonists (eg, clonidine). Hypotension possible with other antihypertensives. Avoid concomitant use with other CYP1A2 inhibitors (eg, amiodarone, mexiletine, propafenone, verapamil, cimetidine, famotidine, other fluoroquinolones, oral contraceptives, acyclovir, ticlopidine, zileuton); if clinically necessary, use caution. May potentiate CNS depression with alcohol, baclofen, benzodiazepines, other CNS depressants. |
| Adverse Reactions |
|
Dry mouth, somnolence, asthenia, dizziness, UTI, constipation, liver injury or elevated liver enzymes, vomiting, speech disorder, blurred vision, dyskinesia, nervousness, pharyngitis, hypotension, bradycardia, hallucinations/psychosis. |
| How Supplied |
|
Tabs, caps—150 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
